- Services
- ABL1 Kinase Domain Mutation Analysis
- Chimerism Assessment by Polymorphic Microsatellite Markers
- Detection of BCR ABL Major Fusion Transcripts
- Detection of BCR ABL Minor Fusion Transcripts
- EndLeukemia RNA Translocation Assay Analysis
- FIP1L1-PDGFRA Fusion Transcript Detection
- FLT3 Mutational Analysis
- hMLH1 Methylation Status
- Immunoglobulin Heavy Chain Gene Rearrangement
- Inv(16)(p13.1q22);CBFB-MYH11 Fusion Transcript Detection
- JAK2 p.V617F Mutational Analysis
- EndLeukemia Assay
- MD EndLymphoma Mutation Analysis
- MD FLT3-ITD Follow up Mutation MRD Analysis
- MD Focused Pharamacogenomics Genotyping Assay
- MD HPV Liquid Biopsy
- MD NPM1 MRD Mutation Analysis
- MDA Mutation Analysis Precision Panel Liquid Biopsy
- MGMT Methylation Status
- Microsatellite Instability Analysis (Tumors)
- PML-RARA/t(15;17) Fusion Transcript Detection
- RUNX1-RUNX1T1/t(8;21)(q22;q22) Fusion Transcript Detection
- Somatic Hypermutation Analysis, IGH
- T cell Receptor Beta Gene Rearrangement
- T cell Receptor Gamma Gene Rearrangement
- TGFB1 Polymorphism Real-Time PCR Genotyping
RUNX1-RUNX1T1/t(8;21) Fusion Transcript Detection
Quantitative RNA-PCR
Indication
This test is for determining the presence or absence of the RUNX1-RUNX1T1 (formerly known as AML1-ETO) fusion transcript associated with the t(8;21)(q22;q22) chromosomal abnormality seen in a about 5% of acute myeloid leukemia (AML) cases, as defined by the 2008 WHO classification and a subset of AML-M2 cases per prior FAB classification. This quantitative test can be used for establishing the diagnosis of AML with recurrent genetic abnormalities per 2008 WHO classification and for monitoring levels of minimal residual disease following therapy.
Methodology
RNA is analyzed for RUNX1-RUNX1T1 fusion by reverse transcription followed by quantitative real-time PCR using the TaqMan method.
Test Parameters
This assay will detect RUNX1-RUNX1T1 fusion transcripts. Values are expressed as a percentage of RUNX1-RUNX1T1 to normalizing ABL1 transcripts. The sensitivity of detection is approximately 1 in 100,000.
Turnaround Time
Five to 10 working days
Sample Requirements
10 ml peripheral blood in purple top tube (EDTA Vacutainer), sent by overnight express mail on wet ice
or
2–5 ml of bone marrow aspirate in purple top tube (EDTA Vacutainer), sent by overnight express mail on wet ice
CPT Codes
81401
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.